Hepatitis C virus (HCV) causes both acute and chronic infection. Acute HCV infections are usually asymptomatic and most do not lead to a life-threatening disease. Around 30% (15–45%) of infected persons spontaneously clear the virus within 6 months of infection without any treatment.

The remaining 70% (55–85%) of persons will develop chronic HCV infection. Of those with chronic HCV infection, the risk of cirrhosis ranges from 15% to 30% within 20 years.

HCV occurs in all WHO regions. The highest burden of disease is in the Eastern Mediterranean Region and European Region, with 12 million people chronically infected in each region. In the South-East Asia Region and the Western Pacific Region, an estimated 10 million people in each region are chronically infected. Nine million people are chronically infected in the African Region and 5 million the Region of the Americas.

The hepatitis C virus is a bloodborne virus. It is most commonly transmitted through:

HCV can be passed from an infected mother to her baby and via sexual practices that lead to exposure to blood (for example, people with multiple sexual partners and among men who have sex with men); however, these modes of transmission are less common.

Hepatitis C is not spread through breast milk, food, water or casual contact such as hugging, kissing and sharing food or drinks with an infected person.

The incubation period for hepatitis C ranges from 2 weeks to 6 months. Following initial infection, approximately 80% of people do not exhibit any symptoms. Those who are acutely symptomatic may exhibit fever, fatigue, decreased appetite, nausea, vomiting, abdominal pain, dark urine, pale faeces, joint pain and jaundice (yellowing of skin and the whites of the eyes).

Because new HCV infections are usually asymptomatic, few people are diagnosed when the infection is recent. In those people who go on to develop chronic HCV infection, the infection is often undiagnosed because it remains asymptomatic until decades after infection when symptoms develop secondary to serious liver damage.

HCV infection is diagnosed in 2 steps:

After a person has been diagnosed with chronic HCV infection, an assessment should be conducted to determine the degree of liver damage (fibrosis and cirrhosis). This can be done by liver biopsy or through a variety of non-invasive tests. The degree of liver damage is used to guide treatment decisions and management of the disease.

Early diagnosis can prevent health problems that may result from infection and prevent transmission of the virus. WHO recommends testing people who may be at increased risk of infection.

In settings with high HCV antibody seroprevalence in the general population (defined as > 2% or > 5% HCV antibody seroprevalence), WHO recommends that all adults have access to and be offered HCV testing with linkage to prevention, care and treatment services.

About 2.3 million people (6.2%) of the estimated 37.7 million living with HIV globally have serological evidence of past or present HCV infection. Chronic liver disease represents a major cause of morbidity and mortality among persons living with HIV globally.

A new infection with HCV does not always require treatment, as the immune response in some people will clear the infection. However, when HCV infection becomes chronic, treatment is necessary. The goal of hepatitis C treatment is to cure the disease.

WHO recommends therapy with pan-genotypic direct-acting antivirals (DAAs) for persons over the age of 12 years. DAAs can cure most persons with HCV infection, and treatment duration is short (usually 12 to 24 weeks), depending on the absence or presence of cirrhosis.

Pan-genotypic DAAs remain expensive in many high- and upper-middle-income countries. However, prices have dropped dramatically in many countries (primarily low-income and lower-middle-income countries) due to the introduction of generic versions of these medicines.

Access to HCV treatment is improving but remains too limited. Of the 58 million persons living with HCV infection globally in 2019, an estimated 21% (15.2 million) knew their diagnosis, and of those diagnosed with chronic HCV infection, around 62% (9.4 million) persons had been treated with DAAs by the end of 2019.

There is no effective vaccine against hepatitis C so prevention depends on reducing the risk of exposure to the virus in health care settings and in higher risk populations. This includes people who inject drugs and men who have sex with men, particularly those infected with HIV or those who are taking pre-exposure prophylaxis against HIV.

Primary prevention interventions recommended by WHO include:

In May 2016, the World Health Assembly adopted the first Global health sector strategy on viral hepatitis, 2016-2021. The strategy highlights the critical role of universal health coverage and sets targets that align with those of the Sustainable Development Goals. The strategy aims to eliminate viral hepatitis as a public health problem by reducing new viral hepatitis infections by 90% and reduce deaths due to viral hepatitis by 65% by 2030.

WHO is working in the following areas to support countries in moving towards achieving the global hepatitis goals under the Sustainable Development Agenda 2030:

WHO organizes the annual World Hepatitis Day campaign (as 1 of its 9 flagship annual health campaigns) to increase awareness and understanding of viral hepatitis. For World Hepatitis Day 2021, WHO is focusing on the theme “Hepatitis Can’t wait” to highlight the urgency of hepatitis elimination with a view to achieving the 2030 elimination targets.

Guidelines & manualsHepatitis C treatmentHepatitis B treatmentMonitoring and evaluation of hepatitis B and CHepatitis E waterborne outbreaksDevelopment of national viral hepatitis plansMore about hepatitisWHO's work on hepatitis  PublicationsWHO's publications